Understanding how immunization affects antibody responses to HIV
Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization
This study is looking at how a special HIV vaccine can help your body make strong antibodies to fight off the virus, and it’s for people interested in how vaccines can be improved to better protect against HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11091605 on NIH RePORTER |
What this research studies
This research investigates how immunization with a specific HIV-1 envelope protein, BG505 SOSIP, can lead to the production of protective neutralizing antibodies. By studying samples from both rhesus macaques and human subjects, the researchers aim to understand the development of these antibodies and their effectiveness against various strains of the virus. The project will also explore how different adjuvants used during immunization can influence the specificity of the antibody responses. This work is crucial for improving future HIV vaccines.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research are individuals who are at risk for HIV infection and are eligible for participation in clinical trials.
Not a fit: Patients who are already HIV positive or those who do not meet the eligibility criteria for the clinical trials may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV vaccines that elicit broader and more potent antibody responses.
How similar studies have performed: Other research has shown promise in using similar immunization strategies to elicit neutralizing antibodies against HIV, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Derdeyn, Cynthia Ann — University of Washington
- Study coordinator: Derdeyn, Cynthia Ann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.